[ Investors » Press Releases ]
2008 | 2007 | 2006 | 2005 | 2004
Press Releases
|
PolyMedix Receives Regulatory Clearance to Initiate Phase I Clinical Study
of Novel Systemic Antibiotic Compound
PMX-30063 The First Defensin Mimetic Systemic Antibiotic Drug
Cleared For Human Clinical Trials
|
|
May 9, 2008
PolyMedix, Inc. (OTC BB: PYMX), an
emerging biotechnology company developing acute care products for infectious diseases and
acute cardiovascular disorders based on biomimetics, has received a notice of no objection from
Health Canada for the Company’s Clinical Trial Application (“CTA”) for its defensin mimetic
antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of human
clinical studies in Canada. PMX-30063 is the first defensin mimetic antibiotic compound cleared
to enter human clinical trials for systemic use, representing an entirely new class of antibiotic
drugs.
Read More |
|
DR. WILLIAM DEGRADO HONORED WITH
THE RALPH F. HIRSCHMANN AWARD IN PEPTIDE CHEMISTRY |
|
April 11, 2008
Dr. William DeGrado, the scientific founder of PolyMedix, Inc. (OTC BB: PYMX), was named the 2008 recipient of the prestigious Ralph F. Hirschmann Award in Peptide Chemistry. The award recognizes a person who has made outstanding contributions in the chemistry, biochemistry, or biophysics of peptides.
Read More |
|
Data on PolyMedix Antimicrobial Polymers presented at American Society of Microbiology 6th Annual Biodefense and Emerging Diseases Research Meeting |
|
February 26, 2008
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechcompany developing acute care products for infectious diseases and acute cardiovascular
disorders based on biomimetics, announced that Dr. Byron Brehm-Stecher presented data yesterday at the “American Society of Microbiology 6th Annual Biodefense and Emerging
Diseases Research Meeting” in Baltimore relating to PolyMedix’s proprietary antimicrobial compounds.
Read More |
|
PolyMedix Appoints Brian Anderson to Board of Directors |
|
January 30, 2008
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, has appointed Brian Anderson to its Board of Directors. Brian Anderson brings over thirty years of experience in the pharmaceutical and biotechnology industries to PolyMedix. Educated at the University of Manitoba, Brian commenced his career in the ...
Read More |
Press releases contain forward-looking statements that involve risks and that could cause PolyMedix’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has tried, wherever possible, to identify these forward-looking statements by using words such as "anticipates," "believes," “hopes,” "estimates," "looks," "expects," "plans," "intends" and similar expressions. Among other things, there can be no assurance that PolyMedix’s compounds will enter or successfully complete clinical testing or be granted regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is included in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forwardlooking
statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
return to top ^ |
